Mass Cytometry in Vaccine Development
This webinar first aired on July 7, 2020, at the Fluidigm Infectious Disease and Oncology Virtual Summit.
In this presentation Patrick Reeves of Harvard Medical School and Massachusetts General Hospital discusses how mass cytometry can benefit vaccine research programs to:
- Overcome hurdles during development
- Deliver valuable insights into efficacy and immune response
- Inform the evaluation of candidate vaccines
Results and lessons from the development of a novel vaccine for Coxiella burnetii and other examples illustrate key benefits, challenges and considerations for integrating mass cytometry into vaccine research programs.
Reeves, P.M., Paul, S.R., Baeten, L. et al. "Novel multiparameter correlates of Coxiella burnetii infection and vaccination identified by longitudinal deep immune profiling." Scientific Reports(2020): 13311.
About the presenter:
Patrick Reeves, PhD
Instructor in Medicine, Harvard Medical School
Team Leader, Vaccine and Immunotherapy Center,
Massachusetts General Hospital
For Research Use Only. Not for use in diagnostic procedures.